Literature DB >> 16893348

Current treatment approaches to early childhood medulloblastoma.

Stefan Rutkowski1.   

Abstract

Treatment of medulloblastoma, the most common malignant brain tumor of childhood, is particularly challenging in very young children, owing to the increased susceptibility of the immature brain to treatment-induced neurocognitive deficits. Three promising strategies have been developed in combination with systemic postoperative chemotherapy, to avoid craniospinal irradiation for young children with nonmetastatic medulloblastoma, these include: high-dose chemotherapy, with and without local radiotherapy; intraventricular chemotherapy; and local radiotherapy. More intensified strategies may be required for metastatic medulloblastoma. Future studies will clarify the prognostic relevance of desmoplasia, postoperative residual tumor and biological markers to improve stratification criteria by risk-adapted treatment recommendations. An international Phase III trial for young children with nonmetastatic medulloblastoma, comparing survival rates and neurocognitive outcomes of different treatment strategies by standardized criteria, is under discussion.

Entities:  

Mesh:

Year:  2006        PMID: 16893348     DOI: 10.1586/14737175.6.8.1211

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  9 in total

1.  Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.

Authors:  André O von Bueren; Katja von Hoff; Torsten Pietsch; Nicolas U Gerber; Monika Warmuth-Metz; Frank Deinlein; Isabella Zwiener; Andreas Faldum; Gudrun Fleischhack; Martin Benesch; Juergen Krauss; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication.

Authors:  Alexander G Weil; Anthony C Wang; Harrison J Westwick; George M Ibrahim; Rojine T Ariani; Louis Crevier; Sebastien Perreault; Tom Davidson; Chi-Hong Tseng; Aria Fallah
Journal:  J Neurooncol       Date:  2016-12-15       Impact factor: 4.130

3.  p53-mediated delayed NF-κB activity enhances etoposide-induced cell death in medulloblastoma.

Authors:  D Meley; D G Spiller; M R H White; H McDowell; B Pizer; V Sée
Journal:  Cell Death Dis       Date:  2010-05-13       Impact factor: 8.469

4.  Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy.

Authors:  Stefan Rutkowski; Nicolas Ulrich Gerber; Katja von Hoff; Astrid Gnekow; Udo Bode; Norbert Graf; Frank Berthold; Günter Henze; Johannes E A Wolff; Monika Warmuth-Metz; Niels Soerensen; Angela Emser; Holger Ottensmeier; Frank Deinlein; Paul-Gerhardt Schlegel; Rolf-Dieter Kortmann; Torsten Pietsch; Joachim Kuehl
Journal:  Neuro Oncol       Date:  2008-09-25       Impact factor: 12.300

5.  Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment.

Authors:  Yu Liang; Maximilian Diehn; Andrew W Bollen; Mark A Israel; Nalin Gupta
Journal:  J Neurooncol       Date:  2007-07-25       Impact factor: 4.130

Review 6.  The clinical implications of medulloblastoma subgroups.

Authors:  Paul A Northcott; Andrey Korshunov; Stefan M Pfister; Michael D Taylor
Journal:  Nat Rev Neurol       Date:  2012-05-08       Impact factor: 42.937

7.  Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice.

Authors:  Joost J C Verhoeff; Lukas J A Stalpers; Annet W Coumou; Kees Koedooder; Cristina Lavini; Cornelis J F Van Noorden; Jaap Haveman; William P Vandertop; Wouter R van Furth
Journal:  Radiat Oncol       Date:  2007-09-26       Impact factor: 3.481

8.  Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway.

Authors:  Kai-Hong Zhao; Can Zhang; Yue Bai; Yan Li; Xun Kang; Jian-Xin Chen; Kun Yao; Tao Jiang; Xiao-Song Zhong; Wen-Bin Li
Journal:  Drug Des Devel Ther       Date:  2017-06-26       Impact factor: 4.162

9.  Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.

Authors:  Onyinyechukwu Okolie; David M Irvin; Juli R Bago; Kevin Sheets; Andrew Satterlee; Abigail G Carey-Ewend; Vivien Lettry; Raluca Dumitru; Scott Elton; Matthew G Ewend; C Ryan Miller; Shawn D Hingtgen
Journal:  PLoS One       Date:  2018-07-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.